About the Transplant Diagnostics Market
Transplantation involves the transfer of cells, tissues, or organs from a donor to a recipient for restoring their function in cases of damage. Donor and recipient cells, tissues, and organs should match or be compatible, otherwise it can lead to transplant rejection. Human leukocyte antigens (HLAs) are present on the surface of the cells that regulate body recognition and reject foreign tissue transplants. In humans, major histocompatibility complex controlled by the genes located on chromosome 6 is responsible for ensuring compatibility between donors and recipients.
Technavio’s analysts forecast the global transplant diagnostics market to grow at a CAGR of 6.63% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global transplant diagnostics market for 2016-2020. To calculate the market size, we consider the revenue generated from the sales of molecular and non-molecular assays. We also consider the revenue generated from pre- and post-transplant diagnostic products and accessories.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Transplant Diagnostics Market 2016-2020
Technavio recognizes the following companies as the key players in the global transplant diagnostics market: Bio-Rad Laboratories, CareDx, Illumina, Immucor, Linkage Biosciences, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Abbott Laboratories, Becton Dickinson, Danaher, F. Hoffmann-La Roche, HistoGenetics, Ortho Clinical Diagnostics, Oxford Immunotec, Qiagen, Siemens, Sigma-Aldrich, and Tosoh Bioscience.
Commenting on the report, an analyst from Technavio’s team said: “A major trend which will boost market growth is product approvals and new launches. The demand and use of transplant diagnostics have led to the rapid increase in the number of new products being launched in the market. Many of these new products have received regulatory approvals, particularly FDA approval in 2015, increasing their accessibility among individuals and medical personnel. In 2015, Thermo Fisher Scientific introduced the NXType NGS HLA typing assay that includes molecular typing products such as SSO, SSP, and SBT technologies. Similarly, in 2015, Qiagen launched the GeneReader NGS system that provides NGS solution for laboratories and helps obtain accurate results.”
According to the report, a key growth driver is the public awareness of organ donation. Awareness of organ donation can help meet the demand for the number of required transplantation. In the US, a research study estimated that about 121,678 people are awaiting organ transplantation. The median waiting time for kidney transplantation is 3.6 years and can vary depending on the person's health, compatibility with donor organ, and availability of organ. The study also reported that over 3,000 new individuals are added to the waiting list for kidney transplant each month, of which about 13 people die each day while waiting for transplantation.
Further, the report states that one challenge that could restrict market growth is the limited technical expertise with regard to advanced transplant diagnostics.
Bio-Rad Laboratories, CareDx, Illumina, Immucor, Linkage Biosciences, Thermo Fisher Scientific, Abbott Laboratories, Becton Dickinson, Danaher, F. Hoffmann-La Roche, HistoGenetics, Ortho Clinical Diagnostics, Oxford Immunotec, Qiagen, Siemens, Sigma-Aldrich, Tosoh Bioscience.